Navigation Links
In Landmark Phase III Head-to-Head Study, Prasugrel Statistically Superior to Clopidogrel in Reducing Risk of Heart Attack
Date:11/4/2007

hreatening and minor bleeding as well as the overall safety and tolerability of prasugrel.

Patients were randomly assigned to one of two treatment groups and given a loading dose of either prasugrel 60 mg or the approved loading dose of clopidogrel 300 mg anytime between randomization and one hour after the completion of the PCI procedure, followed by a daily maintenance dose of either prasugrel 10 mg or clopidogrel 75 mg. All patients also received a daily low dose of aspirin.

Antiplatelet agents are critical for both acute and maintenance therapy to inhibit platelet activation and subsequent aggregation that occur in diseased arteries and as adjunct therapy to invasive procedures such as percutaneous coronary intervention.

About prasugrel

Daiichi Sankyo Company, Limited (TSE: 4568), and Eli Lilly and Company (NYSE: LLY) are co-developing prasugrel, an investigational oral antiplatelet agent invented by Daiichi Sankyo and its Japanese research partner Ube Industries, Ltd., as a potential treatment, initially for patients with acute coronary syndrome undergoing PCI. Prasugrel works by inhibiting platelet activation and subsequent aggregation by blocking the P2Y12 adenosine diphosphate (ADP) receptor on the platelet surface. Antiplatelet agents prevent platelets from clumping or sticking together, which can result in clogged arteries and may lead to heart attack or stroke.

About Daiichi Sankyo Company, Limited

Daiichi Sankyo Company, Limited, established in 2005 after the merger of two leading century-old Japanese pharmaceutical companies, is a global pharmaceutical innovator, continuously generating innovative drugs that enrich the quality of life for patients around the world. The company
'/>"/>

SOURCE Eli Lilly and Company
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine news :

1. South Africa Wins landmark case against pharmaceutical giants
2. Kolkata: Landmark Health City on the Cards
3. Heart Center at Sinai Conducts Landmark Study on Aspirin Resistance
4. Scientists Map Key Landmarks in Human Genome
5. Landmark Study Prompts Rethink of Genetic Code
6. FDA approves Phase 0 trial which tests experimental drugs on humans
7. SARS-Free Taiwan to Mark End Phase of Global Fight
8. S. Africa AIDS in death phase
9. Spray on contraceptive clears Phase I trial
10. Phase 3 trials of two multi-kinase inhibitors against cancer
11. Antigenics Pharmaceuticals plans for Phase III trial of its Melanoma vaccine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... and her research group at the DFG Research Center ... the TU Dresden (CRTD) demonstrated for the first time ... cord in three dimensions from mouse embryonic stem cells. ... interneurons along the dorsal/ventral axis was observed., This study ... " Stem Cell Reports " on 30.10.2014 ., For ...
(Date:10/30/2014)... Florida (PRWEB) October 30, 2014 Timothy, ... visit to Pompano Beach firefighters, showing that you are ... , Timothy met firefighters Tracey and Carl at ... Galuppi’s Restaurant and the Pompano Beach Chamber of Commerce. ... the fire truck, letting Timothy wear his real fireman’s ...
(Date:10/30/2014)... Diego, Calif. (PRWEB) October 30, 2014 ... longer mutually exclusive concepts in the medical-grade skin ... on the development of uniquely potent topical dermatological ... Health System ( http://www.RefinitySkinScience.com ) with patented COSMEDERM®-7 ... available glycolic acid concentrations (50% and 70%) and ...
(Date:10/30/2014)... Paramount Rx, a full-service prescription benefits ... to help people save money through its innovative discount ... prescription drugs in the new health care system, the ... bridge the relationship between consumers, businesses and the pharmacy ... people face today with medical costs is the rising ...
(Date:10/30/2014)... HealthDay Reporter , WEDNESDAY, Oct. 29, ... been identified that appear linked to autism spectrum disorders, ... are on their way to discovering up to 1,000 ... Autism spectrum disorders include a range of developmental disabilities ... An estimated one in 68 U.S. children has an ...
Breaking Medicine News(10 mins):Health News:Reconstruction of a patterned piece of spinal cord in 3-D culture 2Health News:4-year-old InstaKNOT CEO Honors Local Firefighters with Community Support 2Health News:4-year-old InstaKNOT CEO Honors Local Firefighters with Community Support 3Health News:4-year-old InstaKNOT CEO Honors Local Firefighters with Community Support 4Health News:Cosmederm Redefines Peel Science Standard with Launch of Refinity® Skin Health System 2Health News:Cosmederm Redefines Peel Science Standard with Launch of Refinity® Skin Health System 3Health News:Cosmederm Redefines Peel Science Standard with Launch of Refinity® Skin Health System 4Health News:Paramount Rx Discount Card Program Provides Valuable Resources in Midst of Current Health Care Reform 2Health News:Paramount Rx Discount Card Program Provides Valuable Resources in Midst of Current Health Care Reform 3Health News:Discovery of 100-Plus Genes Tied to Autism May Improve Treatments 2Health News:Discovery of 100-Plus Genes Tied to Autism May Improve Treatments 3
... law firm files notice of claim against City of New York ... ... NY (Lexis Nexis) August 28, 2008 -- http://thesandersfirm.com/attorney.asp?attorneyid=14 [Marc ... Sanders, Sanders, Block, Woycik, Viener & Grossman, P.C. in Bronx, New ...
... Efforts to Create Sensible Fire Safety ... Legislation, ... voted to maintain California,s tough fire,standards by striking down proposed fire retardant ... sensible,legislation to address fire safety regulations in the state. The bill would,have ...
... gain access to innovative medical, education and news ... radio channel created for medical professionals by medical ... 157 announced today a new,strategic programming partnership with ... and largest, independent,association for physicians-in-training., Gary Epstein, ...
... American Society for Therapeutic Radiology and Oncology has selected ... honorary member. Dr. Evans will be recognized during the ... during ASTRO,s 50th Annual Meeting in Boston., Dr. Evans ... study of childhood cancer for decades. She was one ...
... cuts risk in half, study finds , , WEDNESDAY, Aug. 27 ... of preterm delivery, cut the rate of cerebral palsy in ... "If deemed to be at high or immediate risk of ... consider using magnesium sulfate to prevent their child from having ...
... treating ,wet, form of the eye disease , , WEDNESDAY, ... States and China have identified the first gene directly ... one of two forms of age-related macular degeneration that ... older Americans. , The discovery, based on work with ...
Cached Medicine News:Health News:New York-Based Sanders Law Firm Files Claim for Good Samaritan Beaten by New York City Police Officers 2Health News:California Senate Rejects Proposed Effort to Weaken Fire Safety Standards 2Health News:ReachMD, LLC Announces New Strategic Partnership With The American Medical Student Association 2Health News:ReachMD, LLC Announces New Strategic Partnership With The American Medical Student Association 3Health News:ASTRO selects pediatric oncologist as 2008 honorary member 2Health News:Magnesium Sulfate Reduces Threat of Cerebral Palsy 2Health News:Magnesium Sulfate Reduces Threat of Cerebral Palsy 3Health News:Gene Linked to 'Dry' Macular Degeneration 2Health News:Gene Linked to 'Dry' Macular Degeneration 3
(Date:10/30/2014)... , La fórmula de ... adquirir tolerancia a la proteína de leche de ... la leche de la vaca (APLV) es la principal alergia ... la APLV se trataba eliminando las proteínas lácteas ... es posible adquirir tolerancia oral en un número ...
(Date:10/30/2014)... YORK , Oct. 29, 2014 ... the basis of test type, technology, product, and ... register the highest growth rate in the newborn ... This high growth is attributed to various nations ... is a fundamental instrument used for expanded newborn ...
(Date:10/30/2014)... Oct. 29, 2014 The global market ... with the introduction of new vaccines. These new ... The World Market. The Kalorama information report examines ... vaccines and developmental vaccines for diseases that are ... but also entire communities from diseases spread by ...
Breaking Medicine Technology:Según expertos reunidos en el Simposio Allergy Day 2Según expertos reunidos en el Simposio Allergy Day 3NewBorn Screening Market by Test Type, Technology (Tandem Mass Spectrometry, Immunoassay, Enzyme Assay, Electrophoresis, Pulse Oximeter), Instrument, Accessories, Reagent & Assay Kit - Global Forecast to 2019 2NewBorn Screening Market by Test Type, Technology (Tandem Mass Spectrometry, Immunoassay, Enzyme Assay, Electrophoresis, Pulse Oximeter), Instrument, Accessories, Reagent & Assay Kit - Global Forecast to 2019 3Vaccines 2014: World Market Analysis, Key Players, Trends, Pediatric and Adult Segments 2Vaccines 2014: World Market Analysis, Key Players, Trends, Pediatric and Adult Segments 3
... 28 Sunesis,Pharmaceuticals, Inc. (Nasdaq: SNSS ) ... (formerly SNS-595) at two major upcoming,oncology conferences., ... clinical trial of,voreloxin in platinum-resistant ovarian cancer patients ... Clinical Oncology (ASCO) Annual Meeting,being held May 30 ...
... for lupus on track for ... 2010 -,- ABthrax(TM) for inhalation anthrax on track to begin delivery fall 2008 -, ... ... GSK to advance darapladib to Phase 3 for atherosclerosis -, ROCKVILLE, Md., May 28 ...
Cached Medicine Technology:Sunesis Pharmaceuticals to Present Interim Clinical Data From Voreloxin (Formerly SNS-595) Ovarian Cancer Trial at 44th ASCO Annual Meeting and Acute Myeloid Leukemia Trials at 13th EHA Congress 2Sunesis Pharmaceuticals to Present Interim Clinical Data From Voreloxin (Formerly SNS-595) Ovarian Cancer Trial at 44th ASCO Annual Meeting and Acute Myeloid Leukemia Trials at 13th EHA Congress 3Human Genome Sciences Reports Progress With Late-Stage Products and New Initiatives 2Human Genome Sciences Reports Progress With Late-Stage Products and New Initiatives 3Human Genome Sciences Reports Progress With Late-Stage Products and New Initiatives 4Human Genome Sciences Reports Progress With Late-Stage Products and New Initiatives 5Human Genome Sciences Reports Progress With Late-Stage Products and New Initiatives 6Human Genome Sciences Reports Progress With Late-Stage Products and New Initiatives 7Human Genome Sciences Reports Progress With Late-Stage Products and New Initiatives 8Human Genome Sciences Reports Progress With Late-Stage Products and New Initiatives 9Human Genome Sciences Reports Progress With Late-Stage Products and New Initiatives 10Human Genome Sciences Reports Progress With Late-Stage Products and New Initiatives 11
... EBV laboratory diagnosis is generally confirmed by a ... the disease however, is not indicated by the ... in 10 - 20 percent of children. ... necessary to fully ascertain the stage of EBV ...
... Bard® Biopsy Instrument and Needle is specially ... goal: a large quality, reliable core sample. ... featuring ultra-sharp tips and polished surfaces for ... of biopsy systems and needle sizes assures ...
... to bring efficiency and quality to routine ... superior technology of fluorescent flow cytometry with ... sampling or batch processing are easily accommodated ... in high volume laboratories. Fluorescent flow ...
... The IsoSleeve™ Source Delivery System incorporates ... design that provides the confidence that each ... prior to implant. Unlike other preloaded needle ... verification of the loading configuration giving you ...
Medicine Products: